戎小萍,楊秋紅,翁海燕,胡 蓉
(1.慈溪婦幼保健院麻醉科,浙江 慈溪 315300; 2.寧波市第一醫(yī)院麻醉科,浙江 寧波 315000)
不同劑量右美托咪定對(duì)婦科腹腔鏡圍手術(shù)期血流動(dòng)力學(xué)等的影響
戎小萍1,楊秋紅2,翁海燕1,胡 蓉1
(1.慈溪婦幼保健院麻醉科,浙江 慈溪 315300; 2.寧波市第一醫(yī)院麻醉科,浙江 寧波 315000)
目的 通過觀察圍手術(shù)期血流動(dòng)力學(xué)及炎癥因子水平變化,探討不同劑量右美托咪定在婦科腹腔鏡手術(shù)中的應(yīng)用。方法 選擇2013年6月至2016年4月120例行婦科腹腔鏡手術(shù)患者,隨機(jī)分為右美托咪定高劑量組(A1)、右美托咪定低劑量組(A2)及對(duì)照組(C),每組40例,A1、A2組分別于麻醉誘導(dǎo)后輸注右美托咪定0.8μg·kg-1·h-1、0.4μg·kg-1·h-1,C組給予等量生理鹽水,分別于麻醉誘導(dǎo)前10min(T0)、氣管插管后1min(T1)、氣腹后5 min(T2)、術(shù)畢(T3)不同時(shí)間點(diǎn)觀察各組患者心率(HR)、平均動(dòng)脈壓(MAP)、去甲腎上腺素(NE)及血清IL-6、IL-10、TNF-α水平變化。結(jié)果 3組患者在T1、T2時(shí)間點(diǎn)MAP、HR、NE均有顯著性差異(F值3.23~5.47,均P<0.05),T3時(shí)間點(diǎn)HR、NE有顯著性差異(F值分別為3.27、3.76,均P<0.05),而MAP無顯著性差異(F=1.09,P>0.05),A1在不同時(shí)間點(diǎn)MAP、HR、NE均波動(dòng)最小,C組患者波動(dòng)最大。3組患者在T1、T2、T3時(shí)間點(diǎn)IL-6、IL-10、TNF-α均有顯著性差異(F值3.31~5.58,均P<0.05),A1組患者T1、T2、T3時(shí)間點(diǎn)IL-6、TNF-α水平均最低,IL-10水平最高,而C組患者IL-6、TNF-6α水平均最高,IL-10水平最低。3組患者氣腹時(shí)間、麻醉恢復(fù)時(shí)間均無顯著性差異(F值分別為0.559、1.677,均P>0.05)。結(jié)論 婦科腹腔鏡手術(shù)中應(yīng)用右美托咪定可減輕圍手術(shù)期炎癥反應(yīng),有利于維持血流動(dòng)力學(xué)穩(wěn)定,其中0.8μg·kg-1·h-1作用顯著。
腹腔鏡;右美托咪定;炎癥因子;血流動(dòng)力學(xué)
腹腔鏡在婦科手術(shù)中應(yīng)用廣泛,與傳統(tǒng)手術(shù)相比腹腔鏡手術(shù)對(duì)腹腔內(nèi)臟器損傷小,創(chuàng)傷面積小,患者手術(shù)過程及術(shù)后恢復(fù)快,痛苦較少,盆腔粘連少[1-2]。但腹腔鏡手術(shù)對(duì)患者呼吸及循環(huán)系統(tǒng)產(chǎn)生一定影響,引發(fā)機(jī)體應(yīng)激反應(yīng)及內(nèi)分泌激素釋放,導(dǎo)致術(shù)中血流動(dòng)力學(xué)變化顯著,故合理選用麻醉方法藥物可減輕患者應(yīng)激反應(yīng)[3-4]。鹽酸右美托咪定(dexmedetomidine,DEX)可抑制交感神經(jīng)興奮,有助于血流動(dòng)力學(xué)穩(wěn)定,減輕腹腔鏡手術(shù)氣腹期間心血管反應(yīng)[5-6]。本文擬通過觀察血流動(dòng)力學(xué)及血清炎癥因子水平變化,探討不同劑量右美托咪定在婦科腹腔鏡手術(shù)中的應(yīng)用,為臨床提供參考。
1.1臨床資料
選擇2013年6月至2016年4月慈溪婦幼保健院120例行婦科腹腔鏡手術(shù)患者,根據(jù)美國(guó)麻醉醫(yī)師協(xié)會(huì)(American society of anesthesiologists,ASA)分為Ⅰ~Ⅱ級(jí),患者年齡21~54歲,體重42~68kg,手術(shù)類型:宮外孕、卵巢囊腫、子宮肌瘤切除術(shù);排除標(biāo)準(zhǔn):心肝腎功能障礙、肺功能異常,先天性心臟病、神經(jīng)系統(tǒng)、內(nèi)分泌、代謝系統(tǒng)疾病患者,貧血及血壓異常者。按照右美托咪定使用情況分為右美托咪定高劑量組(A1)、右美托咪定低劑量組(A2)及對(duì)照組(C),每組40例。本研究已獲本院醫(yī)學(xué)倫理委員會(huì)批準(zhǔn),并與患者簽署知情同意書。
1.2麻醉方法
進(jìn)手術(shù)室后開放靜脈輸注乳酸鈉林格液,全麻誘導(dǎo):0.06mg/kg咪達(dá)唑侖、1.5mg/kg丙泊酚、0.15mg/kg維庫(kù)溴銨、3μg/kg芬太尼,誘導(dǎo)后氣管插管,接呼吸機(jī)人工通氣,參數(shù):潮氣量8~10mL/kg,通氣頻率12~15次/min,吸呼比1:2,氧流量3L/min,二氧化碳分壓35~45mmHg,100%吸入氧濃度。常規(guī)監(jiān)測(cè)血壓、心率及血氧飽和度。麻醉維持:瑞芬太尼輸注0.3~1.0μg·kg-1·min-1,3~5mg·kg-1·h-1丙泊酚,間斷靜注羅庫(kù)溴銨0.04~0.05mg/kg?;颊咴诼樽碚T導(dǎo)前給予10min負(fù)荷量1.0μg/kg右美托咪定,A1、A2組分別于麻醉誘導(dǎo)后輸注右美托咪定0.8、0.4μg·kg-1·h-1至術(shù)畢前30min,C組給予等量生理鹽水。
1.3監(jiān)測(cè)指標(biāo)
分別于麻醉誘導(dǎo)前10min(T0)、氣管插管后1min(T1)、氣腹后5min(T2)、術(shù)畢(T3)不同時(shí)間點(diǎn)觀察各組患者心率(heart rate,HR)、平均動(dòng)脈壓(mean arterial pressure,MAP)、心排血量(cardiac output,CO),并檢測(cè)T0、T1、T2、T3各時(shí)間點(diǎn)血清去甲腎上腺素(noradrenaline,NE)、白細(xì)胞介素-6(interleukin-6,IL-6)IL-6、白細(xì)胞介素-10(interleukin-10,IL-10)、腫瘤壞死因子(tumor necrosis factor,TNF-α)水平變化,電化學(xué)法測(cè)定NE水平,酶聯(lián)免疫吸附測(cè)定(enzyme-linked immuno sorbent assay,ELISA)法測(cè)定血清IL-6、IL-10、TNF-α,試劑盒購(gòu)自于南京建成生物科技有限公司,并記錄患者蘇醒時(shí)間和不良反應(yīng)。
1.4統(tǒng)計(jì)學(xué)方法
2.1患者臨床資料比較
3組患者年齡、身高、體重、身體質(zhì)量指數(shù)(body mass index,BMI)、ASA分級(jí)、手術(shù)時(shí)間、麻醉時(shí)間均無顯著性差異(均P>0.05),見表1。
表1 3組患者臨床資料比較
2.2患者不同時(shí)點(diǎn)血流動(dòng)力學(xué)指標(biāo)變化比較
3組患者在T0點(diǎn)MAP、HR、NE均無顯著性差異(均>0.05),T1、T2時(shí)間點(diǎn)MAP、HR、NE均有顯著性差異(均P<0.05),T3時(shí)間點(diǎn)HR、NE有顯著性差異(均P<0.05),而MAP無顯著性差異(P>0.05),A1在不同時(shí)間點(diǎn)MAP、HR、NE均波動(dòng)最小,C組患者波動(dòng)最大,見表2。
項(xiàng)目A1組(n=40)A2組(n=40)C組(n=40)FPT0 MAP(mmHg)77.80±7.7674.45±8.8075.56±8.220.443>0.05 HR(次/分)84.45±10.9086.36±11.2385.56±11.900.336>0.05 NE(pg/mL)213.56±13.56219.08±15.56220.54±16.570.878>0.05T1 MAP(mmHg)77.45±8.8782.56±7.8088.45±9.904.43<0.05 HR(次/分)75.54±8.5684.23±8.3491.46±9.245.47<0.05 NE(pg/mL)282.56±18.07304.14±20.34344.17±23.43.23<0.05T2 MAP(mmHg)79.34±7.4585.56±9.4494.13±9.055.06<0.05 HR(次/分)71.67±8.9083.58±9.4499.23±10.084.43<0.05 NE(pg/mL)290.15±6.44313.46±8.56378.90±7.765.39<0.05
(轉(zhuǎn)下表)
(續(xù)上表)
項(xiàng)目A1組(n=40)A2組(n=40)C組(n=40)FPT3 MAP(mmHg)77.45±6.6579.07±6.4480.56±7.441.09>0.05 HR(次/分)78.67±6.4478.25±8.3387.24±8.053.27<0.05 NE(pg/mL)264.77±15.34290.45±19.34310.32±17.763.76<0.05
2.3各組患者不同時(shí)點(diǎn)血清IL-6、IL-10、TNF-α水平變化
3組患者在T0點(diǎn)血清IL-6、IL-10、TNF-α均無顯著性差異(均P>0.05),T1、T2、T3時(shí)間點(diǎn)IL-6、IL-10、TNF-α均有顯著性差異(均P<0.05),A1組患者T1、T2、T3時(shí)間點(diǎn)IL-6、TNF-α水平均最低,而IL-10水平最高,見表3。
表3 3組患者不同時(shí)點(diǎn)血流動(dòng)力學(xué)指標(biāo)變化比較±S)
2.4各組患者氣腹時(shí)間及麻醉恢復(fù)時(shí)間比較
3組患者氣腹時(shí)間、麻醉恢復(fù)時(shí)間均無顯著性差異(均P>0.05),見表4。
Table 4 Pneumoperitoneum time and anesthesia recovery time of three groups ±S)
腹腔鏡手術(shù)具有微創(chuàng)、術(shù)后恢復(fù)快、疼痛輕等優(yōu)點(diǎn),隨著腹腔鏡技術(shù)不斷提高及患者對(duì)減小手術(shù)損傷的需求,腹腔鏡手術(shù)在婦科診斷及手術(shù)治療中應(yīng)用廣泛,但二氧化碳?xì)飧箤?dǎo)致的高碳酸血癥及機(jī)械性刺激,引發(fā)系列病理生理變化,激活下丘腦-垂體-腎上腺軸,導(dǎo)致機(jī)體應(yīng)激反應(yīng)[7]。創(chuàng)傷可通過釋放炎癥因子引發(fā)機(jī)體損傷,本研究探討了不同劑量右美托咪定在婦科腹腔鏡手術(shù)應(yīng)用中對(duì)患者炎癥因子及血流動(dòng)力學(xué)影響。
3.1不同麻醉藥物方法對(duì)血流動(dòng)力學(xué)的影響
研究顯示,右美托咪定的使用對(duì)于患者應(yīng)激相關(guān)激素釋放水平及血流動(dòng)力學(xué)指標(biāo)有影響[8]。本研究結(jié)果顯示,3組患者T1、T2時(shí)間點(diǎn)MAP、HR、NE均有顯著性差異(P<0.05),T3時(shí)間點(diǎn)HR、NE有顯著性差異(P<0.05),A1在不同時(shí)間點(diǎn)MAP、HR、NE均波動(dòng)最小,C組患者波動(dòng)最大,提示婦科腹腔鏡手術(shù)中應(yīng)用右美托咪定有利于維持血流動(dòng)力學(xué)穩(wěn)定,其中0.8μg·kg-1·h-1作用顯著。血流動(dòng)力學(xué)變化可能與高碳酸血癥及腹壓增加有關(guān),大腦皮層、邊緣系統(tǒng)及下丘腦對(duì)大腦皮層的透射系統(tǒng)在全身麻醉下可被阻斷,但交感神經(jīng)系統(tǒng)傳到途徑不能在全麻下有效阻斷,手術(shù)傷害刺激交感-腎上腺髓質(zhì)系統(tǒng)興奮,導(dǎo)致血壓升高,右美托咪定可能通過抑制交感神經(jīng)興奮及兒茶酚胺激素釋放,維持血流動(dòng)力學(xué)穩(wěn)定。
3.2不同麻醉藥物方法對(duì)炎癥因子的影響
TNF-α可誘發(fā)細(xì)胞因子級(jí)聯(lián)反應(yīng),刺激IL-6、IL-10釋放,介導(dǎo)炎癥連鎖反應(yīng)[9]。IL-6為促炎癥因子,與機(jī)體損傷程度有一定相關(guān)性,IL-10為多功能負(fù)性調(diào)節(jié)因子,參與免疫細(xì)胞、炎癥細(xì)胞等多種細(xì)胞的生物調(diào)節(jié),具有抗炎及免疫抑制等作用[10]。本研究結(jié)果顯示,T1、T2、T3時(shí)間點(diǎn)IL-6、IL-10、TNF-α均有顯著性差異(均P<0.05),A1組患者的T1、T2、T3時(shí)間點(diǎn)IL-6、TNF-α水平均最低,而IL-10水平最高,C組患者的IL-6、TNF-α水平均最高,而IL-10水平最低,提示婦科腹腔鏡手術(shù)中應(yīng)用右美托咪定可減輕圍手術(shù)期炎癥反應(yīng),其中0.8μg·kg-1·h-1作用顯著。此外,本研究結(jié)果還發(fā)現(xiàn),各組氣腹時(shí)間及麻醉恢復(fù)時(shí)間比較差異無統(tǒng)計(jì)學(xué)意義(P>0.05),提示婦科腹腔鏡手術(shù)中應(yīng)用右美托咪定不影響術(shù)后麻醉恢復(fù),在同等氣腹時(shí)間內(nèi),抑制應(yīng)激激素釋放及調(diào)節(jié)炎癥因子作用右美托咪定高劑量組有一定優(yōu)勢(shì),其通過抑制兒茶酚胺激素及炎癥因子釋放,抑制交感神經(jīng)興奮,減輕術(shù)中應(yīng)激反應(yīng),有助于血流動(dòng)力學(xué)穩(wěn)定,減輕腹腔鏡手術(shù)氣腹期間心血管反應(yīng)。
綜上所述,婦科腹腔鏡手術(shù)中應(yīng)用右美托咪定可減輕圍手術(shù)期的炎癥反應(yīng),有利于維持血流動(dòng)力學(xué)的穩(wěn)定,其中0.8μg·kg-1·h-1作用顯著。
[1]Fawcett W J,Baldini G.Optimal analgesia during major open and laparoscopicabdominal surgery[J].AnesthesiolClin,2015,33(1):65-78.
[2]Bajwa S J,Kulshrestha A.Anaesthesia for laparoscopic surgery:General vs regional anaesthesia[J].J Minim Access Surg,2016,12(1):4-9.
[3]Cheng Y C,Cheng X B,Li X J,etal.Combined general and regionalanesthesia and effects on immune function in patients with benign ovarian tumors treated by laparoscopic therapy[J].Int J ClinExp Med,2013,6(8):716-719.
[4]Buell J F.Laparoscopic hepatectomy under epidural anesthesia without generalendotracheal anesthesia:feasible but applicable[J].Ann Surg,2014,260(2):e2.
[5]Arslan M,Comu F M,Kip G,etal.Effect of dexmedetomidine on erythrocyte deformability during ischaemia-reperfusion injury of heart in diabetic rats[J].BratislLekListy,2014,115(8):494-497.
[6]Kip G,Celik A,Bilge M,etal.Dexmedetomidine protects from post-myocardial ischaemiareperfusion lung damage in diabetic rats[J].Libyan J Med,2015,10:27828.
[7]郭文龍,宋暢.不同劑量右美托咪定對(duì)婦科腹腔鏡手術(shù)圍術(shù)期炎癥因子的影響[J].臨床麻醉學(xué)雜志,2015,31(4):343-345.
[8]馬媛,唐培佳.右美托咪定對(duì)全麻婦科腹腔鏡手術(shù)后蘇醒期應(yīng)激反應(yīng)的影響[J].廣西醫(yī)科大學(xué)學(xué)報(bào),2015,32(2):307-308.
[9]吳嫻,徐海軍,王立偉,等.右美托咪定在婦科腹腔鏡手術(shù)中的應(yīng)用效果研究[J].熱帶醫(yī)學(xué)雜志,2015,15(5):655-658.
[10]張曉英,姜曉春,張新選,等.腹腔鏡以及開腹子宮肌瘤切除術(shù)后CRP、TNF-α、IL-6水平變化分析[J].標(biāo)記免疫分析與臨床,2015,22(9):909-911.
[專業(yè)責(zé)任編輯:陳 寧]
Effect of different doses of dexmedetomidine on perioperative hemodynamics and inflammatory factors in gynecologic laparoscopic surgery
RONG Xiao-ping1, YANG Qiu-hong2, WENG Hai-yan1, HU Rong1
(1.DepartmentofAnesthesiology,CixiMaternityandChildHealthCareHospital,ZhejiangCixi315300,China; 2.DepartmentofAnesthesiology,TheFirstHospitalofNingbo,ZhejiangNingbo315300,China)
Objective To explore the effect of different doses of dexmedetomidine on perioperative hemodynamics and inflammatory factors in gynecologic laparoscopic surgery. Methods A total of 120 patients undergoing gynecological laparoscopic surgery during the period of June 2013 to April 2016 were selected and were randomly divided into high dose group (A1), low dose group (A2) and control group (C) with 40 cases in each. Patients in group A1 and group A2 were given 0.8μg/(kg.h) and 0.4μg/(kg.h) of dexmedetomidine after induction of anesthesia, respectively. Patients in group C were given saline solution. Heart rate (HR), mean arterial pressure (MAP), norepinephrine (NE), IL-6, IL-10 and TNF-α in serum were observed in each group at different time points of 10 min before anesthesia (T0), 1 min after tracheal intubation (T1), 5 min after pneumoperitoneum (T2) and the end of the surgery (T3). Results MAP, HR and NE were significantly different among three groups of patients in T1 and T2 (Fvalue ranged 3.23 to 5.47, respectively, allP<0.05). HR and NE had significant differences (Fvalue was 3.27 and 3.76, respectively, bothP<0.05), while there was no significant difference in MAP at T3 (F=1.09,P>0.05). MAP, HR and NE waves were minimum in group A1 while most volatile in group C at different time points. Three groups of patients were significantly different at T1, T2 and T3 in IL-6, IL-10 and TNF-α (Fvalue ranged 3.31 to 5.58, respectively, allP<0.05). At T1, T2 and T3 IL-6 and TNF-α were lowest but IL-10 was highest in group A1, while IL-6 and TNF-α were highest, but IL-10 was lowest in group C. Three groups of patients were not significantly different in pneumoperitoneum time and anesthesia recovery time (Fvalue was 0.559 and 1.677, respectively, bothP>0.05). Conclusion Use of dexmedetomidine in gynecological laparoscopic surgery can reduce the perioperative inflammatory response, which is helpful to maintain hemodynamic stability. The dose of 0.8μg/(kg.h) is significant.
laparoscopy; dexmedetomidine (DEX); inflammatory cytokines; hemodynamics
2017-01-06
戎小萍(1977-),女,副主任醫(yī)師,主要從事婦產(chǎn)科麻醉工作。
10.3969/j.issn.1673-5293.2017.02.030
R713
A
1673-5293(2017)02-0190-04